Browse > Article

Comparison of entecavir and clevudine for treatment of chronic hepatitis B  

Kim, Dong-Hwan (Department of Internal Medicine, National Health Insurance Corporation Ilsan Hospital)
Kim, Sun-Hye (Department of Internal Medicine, National Health Insurance Corporation Ilsan Hospital)
Kim, Jeong-Ho (Department of Internal Medicine, National Health Insurance Corporation Ilsan Hospital)
Park, Byung-Kyu (Department of Internal Medicine, National Health Insurance Corporation Ilsan Hospital)
Suh, Jeong-Hun (Department of Internal Medicine, National Health Insurance Corporation Ilsan Hospital)
Cho, Yong-Suk (Department of Internal Medicine, National Health Insurance Corporation Ilsan Hospital)
Choi, Jong-Won (Department of Internal Medicine, National Health Insurance Corporation Ilsan Hospital)
Lee, Chun-Kyon (Department of Internal Medicine, National Health Insurance Corporation Ilsan Hospital)
Publication Information
The Korean Journal of Medicine / v.78, no.5, 2010 , pp. 595-601 More about this Journal
Abstract
Background/Aims: Entecavir (ETV) and clevudine (CLV) are potent inhibitors of hepatitis B virus (HBV) DNA polymerase and have demonstrated clinical efficacy. No comparative study has reported on these two medications among patients with naive chronic hepatitis B (CHB). We assessed the clinical outcome of CHB patients treated with either ETV or CLV. Methods: A nonrandomized comparative study was conducted retrospectively. The clinical results from treatments of either 0.5 mg ETV (n=56) or 30 mg CLV (n=45) were analyzed during a 1 year period. The median reduction in serum HBV DNA, undetectable HBV DNA, HBeAg seroconversion, and normalization of alanine transaminase (ALT) were compared between the two groups. Results: After 1 year on antiviral therapy, the median reduction in serum HBV DNA from baseline to the endpoint was greater in patients in the ETV group than in those in the CLV (5.73 vs. 4.5 log copies/mL, p=0.009) group. ALT normalization occurred in 85.5% (47/55) of the ETV cases and 77.3% (34/40) of the CLV cases (p=0.215). HBV DNA was undetectable in 80.0% (44/55) of the ETV group and 78.0% (32/41) of the CLV group (p=0.505). HBeAg seroconversion occurred in 15.4% (6/39) of those administered ETV and in 14.3% (4/28) administered CLV (p=0.593). Within 12 months, a virological breakthrough was documented in three patients undergoing CLV treatment, and CLV-related myopathy developed in three other patients. Conclusions: ETV and CLV showed excellent antiviral effects in patients with CHB. ETV was superior for viral suppression and showed fewer side effects than CLV.
Keywords
Chronic hepatitis B; Entecavir; Clevudine;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 김병국, 권소영, 최원혁, 고순영, 이창홍, 오지영. 만성 B형간염 환자에서 클레부딘 치료의 항바이러스 효과 및 안전성 연구: 바이러스 돌파 발생과 근육관련 증상 발현을 중심으로. 대한간학회지 15(3 Suppl):S191, 2009
2 Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, DeHertogh D, Wilber R, Zink RC, Cross A, Colonno R, Fernandes L. Entecavir versus lamivudine for patients with HBeAgnegative chronic hepatitis B. N Engl J Med 354:1011-1020, 2006   DOI   ScienceOn
3 정인두, 박능화, 김병철, 박지현, 서광현, 김대현, 주광로, 김도하. HBeAg 음성 만성 B형 간질환에서 Lamivudine의 치료 효과. 대한간학회지 9:69-78, 2003
4 Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351:1521-1531, 2004   DOI   ScienceOn
5 설혜령, 김형준, 이현웅, 김성진, 정선주, 황승재, 최창환, 오형철, 김정욱, 도재혁, 김재규, 장세경, 박실무. 치료 경험이 없는 만성 B형간염 환자에서 엔테카비어와 클레부딘의 24주간 치료효과에 대한 비교. 대한간학회지 14(3 Suppl):S138, 2008
6 조문숙, 김주현, 이서영, 한우진, 권오상, 김연수, 최덕주. 만성 B형간염에서 클레부딘 장기 투여시 발생한 근육병증. 대한간학회지 15(3 Suppl):S145, 2009
7 장제혁, 명형준, 김희섭, 정숙향, 김진욱, 황진혁, 이상협. 만성 B형간염 초치료제로서 클레부딘의 효과와 치료예측인자. 대한간학회지 15(3 Suppl):S204, 2009
8 Lee HS, Chung YH, Lee K, Byun KS, Paik SW, Han JY, Yoo K, Yoo HW, Lee JH, Yoo BC. A 12-week clevudine therapy showed potent and durable antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology 43:982-988, 2006   DOI   ScienceOn
9 이창민, 민현주, 하창윤, 김현진, 김태효, 정운태, 이옥재, 최순필, 박종호, 조대현, 심상곤. 만성 B형간염 환자에서 클레부딘의 48주간 초치료의 효과. 대한간학회지 15(3 Suppl):S198, 2009
10 Kao JH, Chen DS. Global control of hepatitis B virus infection. Lancet Infect Dis 2:395-403, 2002   DOI   ScienceOn
11 Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, Lok AS, Han KH, Goodman Z, Zhu J, Cross A, DeHertogh D, Wilber R, Colonno R, Apelian D. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 354:1001-1010, 2006   DOI   ScienceOn
12 Lampertico P. Entecavir versus lamivudine for HBeAg positive and negative chronic hepatitis B. J Hepatol 45:457-460, 2006   DOI   PUBMED   ScienceOn
13 Levine S, Hernandez D, Yamanaka G, Zhang S, Rose R, Weinheimer S, Colonno R. Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrob Agents Chemother 46:2525-2532, 2002   DOI   ScienceOn
14 Matthews SJ. Entecavir for the treatment of chronic hepatitis B virus infection. Clin Ther 28:184-203, 2006   DOI   PUBMED   ScienceOn
15 Colonno RJ, Genovesi EV, Medina I, Lamb L, Durham SK, Huang ML, Corey L, Littlejohn M, Locarnini S, Tennant BC, Rose B, Clark JM. Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection. J Infect Dis 184:1236-1245, 2001   DOI   ScienceOn
16 이현웅, 김형준, 김경아, 이준성, 백은경, 김기성, 이승용, 차봉기, 오형철, 최창환, 김정욱, 도재혁, 김재규, 장세경. 만성 B형간염 환자의 초치료로서 엔테카비어와 클레부딘의 72주간 치료 효과에 대한 비교. 대한간학회지 15(3 Suppl):S150, 2009
17 Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295:65-73, 2006   DOI   ScienceOn
18 Korba BE, Furman PA, Otto MJ. Clevudine: a potent inhibitor of hepatitis B virus in vitro and in vivo. Expert Rev Anti Infect Ther 4:549-561, 2006   DOI   PUBMED   ScienceOn
19 Yoo BC, Kim JH, Chung YH, Lee KS, Paik SW, Ryu SH, Han BH, Han JY, Byun KS, Cho M, Lee HJ, Kim TH, Cho SH, Park JW, Um SH, Hwang SG, Kim YS, Lee YJ, Chon CY, Kim BI, Lee YS, Yang JM, Kim HC, Hwang JS, Choi SK, Kweon YO, Jeong SH, Lee MS, Choi JY, Kim DG, Kim YS, Lee HY, Yoo K, Yoo HW, Lee HS. Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology 45:1172-1178, 2007   DOI   ScienceOn
20 Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 130:678-686, 2006   DOI   ScienceOn
21 Marcellin P, Mommeja-Marin H, Sacks SL, Lau GK, Sereni D, Bronowicki JP, Conway B, Trepo C, Blum MR, Yoo BC, Mondou E, Sorbel J, Snow A, Rousseau F, Lee HS. A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B. Hepatology 40:140-148, 2004   DOI   ScienceOn
22 고순영, 권소영, 최원혁, 김병국, 이창용. 만성 B형간염 환자에서 클레부딘 치료의 항바이러스 효과에 관한 연구. 대한간학회지 14(3 Suppl):S42, 2008
23 Gish RG, Lok AS, Chang TT, de Man RA, Gadano A, Sollano J, Han KH, Chao YC, Lee SD, Harris M, Yang J, Colonno R, Brett-Smith H. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 133: 1437-1444, 2007   DOI   ScienceOn
24 Lim SG, Krastev Z, Ng TM, Mechkov G, Kotzev IA, Chan S, Mondou E, Snow A, Sorbel J, Rousseau F. Randomized, double- blind study of emtricitabine (FTC) plus clevudine versus FTC alone in treatment of chronic hepatitis B. Antimicrob Agents Chemother 50:1642-1648, 2006   DOI   ScienceOn
25 Chang TT, Gish RG, Hadziyannis SJ, Cianciara J, Rizzetto M, Schiff ER, Pastore G, Bacon BR, Poynard T, Joshi S, Klesczewski KS, Thiry A, Rose RE, Colonno R, Hindes RG. A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudinerefractory chronic hepatitis B patients. Gastroenterology 129: 1198-1209, 2005   DOI   PUBMED   ScienceOn
26 이헌주, 은종렬, 이창형, 황재석, 서정일, 김병석, 장병국. 만성 B형간질환에서 핵산유사체 치료경험이 없는 환자와 라미부딘 경험자에서의 클레부딘 치료. 대한간학회지 15:179-192, 2009   DOI